433231-75-5

Upstream product

• 433231-73-3 4-(2-{(1R,2R,3R,5S)-5-Acetoxy-2-[(E)-(S)-4-(1-ethyl-cyclobutyl)-4-hydroxy-but-1-enyl]-3-hydroxy-cyclopentyl}-ethyl)-benzoic acid methyl ester 
• 69739-34-0 t-butyldimethylsiyl triflate 

Downstream Products

• 433231-73-3 4-(2-{(1R,2R,3R,5S)-5-Acetoxy-2-[(E)-(S)-4-(1-ethyl-cyclobutyl)-4-hydroxy-but-1-enyl]-3-hydroxy-cyclopentyl}-ethyl)-benzoic acid methyl ester 
• 433231-77-7 4-(2-{(1R,2R,3R,5R)-5-Chloro-2-[(E)-(S)-4-(1-ethyl-cyclobutyl)-4-hydroxy-but-1-enyl]-3-hydroxy-cyclopentyl}-ethyl)-benzoic acid methyl ester 

Relevant academic research and scientific papers

Development of a highly selective EP2-receptor agonist. Part 2: Identification of 16-Hydroxy-17,17-trimethylene 9β-chloro PGF derivatives

Further chemical modification of 1a and 2 was undertaken to identify a more chemically stable selective EP2-receptor agonist for development as a clinical candidate. 9β-Chloro PG analogues 4a e and 5a, c e were found to be potent and selective EP2-receptor agonists. Among them, the compound 4aLy, which is a chemically stabilized lysine salt of 4a, exhibited an excellent profile both in biological activities and physicochemical properties. The agonist 4aLy was found to suppress uterine motility in anesthetized pregnant rats, while PGE2 stimulated uterine motility. Structure activity relationships (SARs) are discussed. Copyright